GlassScriptPhysician profile
Mohammed Ibrahim Tarrabain
NPI 1437349180
$13,949.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,393.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,756.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.34 | 2019 | |
| Vivus LLC | $29.24 | 2019 | |
| Lilly USA, LLC | $25.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.28 | 2019 | |
| Astellas Pharma US INC | $14.87 | 2019 | |
| Shire North American Group INC | $13.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.30 | 2019 | |
| Eisai INC. | $12.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Tarrabain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.